PCM
CLDX icon

Prelude Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Prelude Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,066
Closed -$632K – 1175
2025
Q2 		$632K Buy
+31,066
New +$605K 0.06% 374
2024
Q2 		– Sell
-16,300
Closed -$684K – 1251
2024
Q1 		$684K Sell
16,300
-10,212
-39% -$419K 0.04% 502
2023
Q4 		$1.05M Buy
+26,512
New +$780K 0.07% 290
2017
Q4 		– Sell
-1,220
Closed -$52K – 1393
2017
Q3 		$52K Buy
+1,220
New +$45.7K ﹤0.01% 1093
2015
Q3 		– Sell
-926
Closed -$350K – 1515
2015
Q2 		$350K Hold
926
– – 0.05% 404
2015
Q1 		$387K Buy
+926
New +$331K 0.05% 418

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return